Suzuken (9987) Fundamentals 2026 — P/E 9.5x, Revenue Analysis | SniperIQ
Suzuken (9987) is a JP-listed Healthcare company in Medical - Distribution with a market capitalization of ¥351.4B, trading at ¥5196.00 on the JPX. This SniperIQ fundamentals page covers Suzuken's valuation (P/E 9.5x, P/B 0.8x), profitability (net margin 1.5%), revenue (¥2.49T in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Suzuken's market cap?
Suzuken (9987) has a market capitalization of approximately ¥351.4B, trading at ¥5196.00 on the JPX. Market cap moves with the live share price.
What is Suzuken's P/E ratio?
Suzuken's trailing twelve-month P/E ratio is 9.5x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Suzuken?
Suzuken runs a net profit margin of 1.5%, a gross margin of 7.7%, and an operating margin of 1.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Suzuken generate?
Suzuken reported revenue of ¥2.49T for fiscal year 2026, with net income of ¥38.1B and earnings per share (EPS) of 545.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Suzuken pay a dividend?
Suzuken offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Suzuken financially healthy?
Suzuken carries a debt-to-equity ratio of 0.00x and a current ratio of 1.23x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Suzuken a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Suzuken (9987) the key facts are: market cap ¥351.4B, P/E 9.5x, revenue ¥2.49T, 52-week range 4810-6668. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Suzuken's full fundamentals live
Get Suzuken's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.